Seres Therapeutics, Takeda & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

The FDA granted Seres Therapeutics' SER-287 orphan drug designation. SER-287 treats pediatric ulcerative colitis.

The FDA approved Ferring Pharmaceutical's Clenpiq, a low-volume colonoscopy prep solution.

Takeda appointed Toshio Fujimoto, MD, to serve as the general manager of the Health Innovation Park in Shonan, Japan.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.